ClinicalTrials.gg
RecruitingNCT06691165Updated Nov 18, 2025

Improving 24-hour Blood Pressure Stability in Spinal Cord Injury With Low Oxygen Therapy

A Phase 1/2 interventional study of Low oxygen therapy (LOT) in Spinal Cord Injury, sponsored by Glen Foster. Recruiting at 2 sites in Canada. Open to participants aged 19 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by Glen Foster · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
19 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 204 studies in Spinal Cord Injuries with a site in Canada — 67 open to participants now, 74 under way, 4 of them phase 3. Spinal Cord Injuries · Canada.

Planned enrollment
136th of 179
10 · median 24
Started
2025
with 11 others
Phase 1/2
5 of 204
1 open now
Primary completion
2026-12
later than 32 of 73 live
Registered
170th of 204
by date

Among the 204 studies in Spinal Cord Injuries with a site in Canada, this one is the 136th largest by planned enrollment of the 179 interventional ones that give a count, is one of 12 that started in 2025, is one of 5 in phase 1/2, reaches primary completion later than 32 of the 73 other live ones, and was the 170th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

67 of the 204 studies in Spinal Cord Injuries with a site in Canada are open now. Recruiting first, the newest first:

61 more — sign in →

All 67 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 19 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 204 studies in Spinal Cord Injuries with a site in Canada, or all of them as a file.
02

Study summary

This study examines the effects of low oxygen therapy (LOT) on the stability of 24-hour blood pressure in persons with chronic cervical spinal cord injury.

This study will examine if brief episodes of breathing lower oxygen, termed low oxygen therapy (LOT), which has been shown to enhance autonomic nervous system activity, can improve blood pressure stability in individuals with spinal cord injury. The research team will assess 24-hour blood pressure, as well as cardiac, vascular, and autonomic function before and after a 4-day LOT treatment intervention. This study will advance current understanding of treatments to mitigate cardiovascular disease risk in people with spinal cord injuries.

Read the detailed description

Spinal cord injury (SCI) interrupts signals travelling down from the brain to the rest of the body below the level of the injury. The loss of nerve connections involved in cardiovascular control results in blood pressure instability. This can lead to sudden drops in blood pressure, such as when shifting upright or during transfers, or sudden increases during autonomic dysreflexia. These swings in blood pressure are linked to a nearly 4-fold increase in the risk of cardiovascular disease in people with SCI.

Repeated, brief exposure to breathing lower levels of oxygen, termed low oxygen therapy, has been shown to stimulate adaptation in the nervous system. This neuroplasticity increases the activity of cardiovascular control circuits, and has been shown to increase blood pressure in able-bodied individuals. Similar effects on respiratory and motor function in people with SCI, but the effects on the cardiovascular system have not been studied in this population.

This study will test the effects of a 4-day low oxygen therapy intervention on 24-hour blood pressure stability in people with chronic cervical SCI. By assessing mechanisms of cardiac, vascular, and autonomic function, this study aims to improve current understanding of the therapeutic potential of low oxygen therapy to mitigate cardiovascular disease risk in SCI.

03

Conditions studied

  • Spinal Cord Injury

Keywords

  • Low oxygen therapy
  • Intermittent hypoxia
  • Blood pressure
  • Spinal cord injury
  • Cardiac function
  • Sympathetic nervous system
04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are between the ages of 19-65
  • Living with a chronic cervical (at or above T1) spinal cord injury of at least one year
  • Are fluent in english

Exclusion criteria

Exclusion Criteria:

  • High-cervical injuries requiring ventilator assistance to breathe will be excluded on account of the necessity of the facemask for the delivery of hypoxia
  • Unhealed fracture, contracture, or pressure sore that might interfere with participants' ability to complete the protocol
  • Additional concurrent neurological conditions (e.g., multiple sclerosis, Parkinson disease, stroke or brain injury)
  • Uncontrolled cardiovascular or pulmonary disease
  • Severe neuropathic pain
  • Severe recurrent autonomic dysreflexia
  • History of seizure disorders
  • Known pregnancy
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Room air control; lot oxygen therapy; recovery/washout

    Participants with chronic cervical spinal cord injury will undergo a 4-day low oxygen therapy intervention. Measurements will first be taken at least three days before the beginning of the intervention to establish baseline characteristics, immediately before and after the first day of the intervention to assess the acute response to the intervention, and on the first and fourth days after the end of the intervention to assess persistent effects and washout.

    Drug: Low oxygen therapy (LOT)

Interventions

  • DrugLow oxygen therapy (LOT)

    Participants will breathe variable concentrations of inspired oxygen, carbon dioxide, and nitrogen. The concentrations will be adjusted on a breath-by-breath basis to maintain end-tidal targets. Each daily session of the intervention will consist of forty 1-minute intervals. Each 1-minute interval will consist of 40 seconds of hypercapnic hypoxia, increasing the partial pressure of end-tidal carbon dioxide by +4 mmHg and decreasing the partial pressure of end-tidal oxygen to 45 mmHg, followed by 20 seconds in simulated room air to return to baseline carbon dioxide and oxygen levels.

    Also known as: Intermittent hypoxia

06

What researchers measure

Primary outcomes

  1. Change in 24-hour blood pressure

    Mean arterial blood pressure (mmHg), averaged across 24 hours

    Time frame: Change from baseline of 24-hour mean arterial blood pressure at 1-day post-intervention

Secondary outcomes

  1. Change in 24-hour blood pressure stability

    Mean arterial blood pressure (mmHg), standard deviation across 24 hours

    Time frame: Change from baseline of the standard deviation of 24-hour mean arterial blood pressure at 1-day post-intervention

  2. Change in left-ventricular contractility

    Indices of load-independent pressure generation during systole: Estimated end-systolic elastance (mmHg/ml); end-systolic pressure-volume relationship slopes (mmHg/ml)

    Time frame: Change from baseline of left ventricular contractility indices immediately after the first intervention session, and at 1-day and 4-days post-intervention

  3. Change in baroreflex gain

    Indices of baroreflex sensitivity: Relationship of systolic blood pressure against subsequent R-R interval duration during Valsalva Maneuver phases II and IV (ms/mmHg); spectral power of low-frequency resting blood pressure variability

    Time frame: Change from baseline of baroreflex gain indices immediately after first intervention session, and at 1-day and 4-days post-intervention

  4. Change in circulating catecholamines

    Venous plasma concentrations of norepinephrine and epinephrine (mmol/L)

    Time frame: Change from baseline of circulating catecholamines immediately after first intervention session, and at 1-day and 4-days post-intervention

  5. Change in cerebral neurovascular coupling and autoregulation

    Middle and posterior cerebral artery blood flow velocity (cm/s)

    Time frame: Change from baseline of the responses of cerebral blood flow indices during a visual stimulus and head-up tilt immediately after first intervention session, and at 1-day and 4-days post-intervention

  6. Change in renal filtration function

    Humoral renal biomarkers (e.g., serum creatinine)

    Time frame: Change from baseline in renal biomarkers and blood flow at rest immediately after first intervention session, and at 1-day and 4-days post-intervention

  7. Change in flow-mediated dilation

    Brachial artery flow-mediated dilation following 5-minute forearm blood flow occlusion (mm)

    Time frame: Change from baseline in flow-mediated dilation immediately after first intervention session, and at 1-day and 4-days post-intervention

  8. Change in tonic peripheral chemoreflex activity

    Magnitude of hyperoxic ventilatory depression (L/min)

    Time frame: Change from baseline in the magnitude of ventilatory depression in hyperoxia immediately after first intervention session, and at 1-day and 4-days post-intervention

  9. Change in renal vascular function

    Renal artery blood flow velocity (cm/s)

    Time frame: Change in renal blood flow velocity from baseline during the first and final hypoxia cycles on the first session of the intervention

07

Study locations

2 of 2 sites recruiting
  • UBC Okanagan
    Kelowna, British Columbia V1V 1V7, Canada
    Recruiting
  • International Collaboration on Repair Discoveries (ICORD)
    Vancouver, British Columbia V5Z 1N1, Canada
    Recruiting
08

References and documents

Publications

  • Vermeulen TD, Benbaruj J, Brown CV, Shafer BM, Floras JS, Foster GE. Peripheral chemoreflex contribution to ventilatory long-term facilitation induced by acute intermittent hypercapnic hypoxia in males and females. J Physiol. 2020 Oct;598(20):4713-4730. doi: 10.1113/JP280458. Epub 2020 Aug 19. PubMed 32744340 ↗
  • Claydon VE, Steeves JD, Krassioukov A. Orthostatic hypotension following spinal cord injury: understanding clinical pathophysiology. Spinal Cord. 2006 Jun;44(6):341-51. doi: 10.1038/sj.sc.3101855. Epub 2005 Nov 22. PubMed 16304564 ↗
  • Vose AK, Welch JF, Nair J, Dale EA, Fox EJ, Muir GD, Trumbower RD, Mitchell GS. Therapeutic acute intermittent hypoxia: A translational roadmap for spinal cord injury and neuromuscular disease. Exp Neurol. 2022 Jan;347:113891. doi: 10.1016/j.expneurol.2021.113891. Epub 2021 Oct 9. PubMed 34637802 ↗
  • Perim RR, Vinit S, Mitchell GS. Cervical spinal hemisection effects on spinal tissue oxygenation and long-term facilitation of phrenic, renal and splanchnic sympathetic nerve activity. Exp Neurol. 2023 Oct;368:114478. doi: 10.1016/j.expneurol.2023.114478. Epub 2023 Jul 13. PubMed 37451584 ↗
  • Welch JF, Vose AK, Cavka K, Brunetti G, DeMark LA, Snyder H, Wauneka CN, Tonuzi G, Nair J, Mitchell GS, Fox EJ. Cardiorespiratory Responses to Acute Intermittent Hypoxia in Humans With Chronic Spinal Cord Injury. J Neurotrauma. 2024 Sep;41(17-18):2114-2124. doi: 10.1089/neu.2023.0353. Epub 2024 Apr 18. PubMed 38468543 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 14 months after the start.

Of 24 phase 1/2 interventional studies under Spinal Cord Injuries, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2024
First posted
Nov 15, 2024
StartActual
Oct 23, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06691165
Lead sponsor
Glen Foster
Responsible party
Glen Foster (Professor, University of British Columbia) — Sponsor-investigator
First posted
Nov 15, 2024
Start date
Oct 23, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 18, 2025

Study contacts

Scott F Thrall, M.Sc.
Contact
sthrall@student.ubc.ca
+1 250-807-8083
Glen E Foster, Ph.D.
Contact
glen.foster@ubc.ca
+1 250-807-8224

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion